Sun Pharmaceutical Industries and Cassiopea, a subsidiary of Cosmo Pharmaceuticals N.V. announced the signing of addendums to the license and supply agreements for WINLEVI (clascoterone) cream 1% expanding the territory to include Japan, Australia, New Zealand, Brazil, Mexico and Russia. In 2021, Sun Pharma and Cassiopea had signed License and Supply Agreements for the United States and Canada markets. Sun Pharma launched WINLEVI in the US market in November 2021.
Sun Pharmaceutical Industries on Tuesday said it has expanded the scope of its partnership with Cassiopea regarding a medication to treat acne. It has inked addendums to the licence and supply agreements for WINLEVI (clascoterone) cream 1 per cent, expanding the territory to include Japan, Australia, New Zealand, Brazil, Mexico and Russia.
Sun Pharma and specialty pharma firm Cassiopea SpA on Tuesday announced consummation of their exclusive licence and supply agreements for Winlevi cream used for treatment of acne vulgaris in patients 12 years and older.
Sun Pharmaceutical Industries Ltd has signed license and supply agreement with Cassiopea SpA for Winlevi (clascoterone cream 1%) in the United States and Canada.
Sun Pharmaceutical Industries Ltd has signed license and supply agreement with Cassiopea SpA for Winlevi (clascoterone cream 1%) in the United States and Canada.
ZURICH (Reuters) - Swiss-listed drugmaker Cassiopea said on Thursday it won approval for its first medicine, an acne treatment, from the U.S. Food and Drug Administration, setting the stage for a likely capital increase to support its launch.
Swiss-listed drugmaker Cassiopea said on Thursday it won approval for its first medicine, an acne treatment, from the U.S. Food and Drug Administration, setting the stage for a likely capital increase to support its launch.